This mechanistic rationale highlights pDCs targeting as a potential adjunctive strategy in chronic HIV infection—by curtailing the chief source of IFN-I, it may be possible to break the cycle of IFN-driven inflammation and immune dysfunction, thereby bolstering host immunity and improving clinical outcomes [6]. Here, IFNA1 is linked to HIV infectious disease.